Madīnat Sittah Uktūbar, Egypt
Madīnat Sittah Uktūbar, Egypt

Time filter

Source Type

News Article | January 20, 2016
Site: www.cemag.us

Gardeners often use sheets of plastic with strategically placed holes to allow their plants to grow but keep weeds from taking root. Scientists from UCLA’s California NanoSystems Institute have found that the same basic approach is an effective way to place molecules in the specific patterns they need within tiny nanoelectronic devices. The technique could be useful in creating sensors that are small enough to record brain signals. Led by Paul Weiss, a distinguished professor of chemistry and biochemistry, the researchers developed a sheet of graphene material with minuscule holes in it that they could then place on a gold substrate, a substance well suited for these devices. The holes allow molecules to attach to the gold exactly where the scientists want them, creating patterns that control the physical shape and electronic properties of devices that are 10,000 times smaller than the width of a human hair. A paper about the work was published in the journal ACS Nano. “We wanted to develop a mask to place molecules only where we wanted them on a stencil on the underlying gold substrate,” Weiss says. “We knew how to attach molecules to gold as a first step toward making the patterns we need for the electronic function of nanodevices. But the new step here was preventing the patterning on the gold in places where the graphene was. The exact placement of molecules enables us to determine exact patterning, which is key to our goal of building nanoelectronic devices like biosensors.” With the advance, making nanoelectronic and nanobioelectronic devices could be much more efficient than current methods of molecular patterning, which use a technique called nanolithography. Weiss said that could be especially useful for scientists who are trying to place molecular sensors on the surface of gold or other nanomaterials that are used for their sensitivity and selectivity but difficult to work with because of their size. Neurosensors that could measure brain cell and circuit function in real time could reveal new insights into diseases like autism and depression. Ultimately, Weiss said, the researchers hope to be able to stimulate individual brain circuits using sensors so they can predict key chemical differences between function and malfunction in the brain. This knowledge could then be used to develop targets for new generations of treatments for neurological diseases. The paper’s other authors were John Thomas, Shan Jiang, Nathan Weiss, and Xiangfeng Duan of UCLA, and Matthew Gethers and William Goddard III of Caltech. Research for the study was conducted in the Electron Imaging Center for Nanomachines and the Nano and Pico Characterization Laboratory, which are both parts of the California NanoSystems Institute. The research was supported by the U.S. Department of Energy, the National Science Foundation, the Caltech EAS Discovery Fund, and UCLA.


ROCKVILLE, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced that it has been issued a patent from the United States Patent and Trademark Office (USPTO) covering RX-21101 for the targeted delivery of docetaxel directly into cancer tumor cells using a nano-polymer conjugate technology. "We are pleased to expand our intellectual property covering our unique and innovative targeting technologies in preclinical development. RX-21101 is the first proof of concept candidate from our Nano-Polymer-Drug Conjugate Systems (NPDCS). Our nanotechnology drug conjugate candidates address the large and immediate market for widely used chemotherapies, and they are a complement to our portfolio of proprietary compounds currently in clinical development,” commented Rexahn's CEO, Peter D. Suzdak, Ph.D. RX-21101 is a nano-polymer conjugate with docetaxel bound to the polymer backbone together with a targeting moiety. The targeting moiety directs the bound drug to the cancer cell, thereby bypassing healthy cells leading to enhanced efficacy with the potential for reduced side effects. Once inside the cancer cell, the complex is metabolized yielding the free anticancer compound.  It is the combination of the nano-polymer and the targeting moiety that makes Rexahn’s technology unique and increases the precision of delivery into the cancer cell. RX-21101 has been selected by the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory for its preclinical development program in 2015. In addition, Rexahn has issued patents covering other nano-polymer conjugate systems including the carboxypropyl-methacrylamide (CPMA) nano-polymer-drug conjugate platform which offers several major advantages over existing drug conjugate systems including the ability to target the delivery of anticancer agents to cancer cells, high water solubility, increased bioavailability and the flexibility to covalently bind multiple structurally diverse classes of compounds to its chemical backbone. Rexahn is actively pursuing other potential drug conjugate candidates with our CPMA platform for the treatment of solid tumors. RX-21101 is a chemotherapeutic that combines Rexahn’s nano-drug delivery and targeting technology with docetaxel, a widely used FDA-approved chemo drug. RX-21101 may be more effective and better tolerated than docetaxel and preclinical studies have shown the potential to reduce peripheral neuropathy, a debilitating side effect of docetaxel.  Potential indications include breast, ovarian, prostate and lung cancer. Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer.  The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that certain of Rexahn's product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments.  The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: RX-3117, Supinoxin™, and Archexin®, and a novel nano-polymer conjugate platform technology that targets the delivery of FDA approved chemotherapies directly into cancer tumor cells.  For more information about the Company and its oncology programs, please visit www.rexahn.com. To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, enrollments in clinical trials, the path of clinical trials and development activities, and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer; drug candidates being in early stages of development, including in preclinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration; and the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


Abstract: Gardeners often use sheets of plastic with strategically placed holes to allow their plants to grow but keep weeds from taking root. Scientists from UCLA’s California NanoSystems Institute have found that the same basic approach is an effective way to place molecules in the specific patterns they need within tiny nanoelectronic devices. The technique could be useful in creating sensors that are small enough to record brain signals. Led by Paul Weiss, a distinguished professor of chemistry and biochemistry, the researchers developed a sheet of graphene material with minuscule holes in it that they could then place on a gold substrate, a substance well suited for these devices. The holes allow molecules to attach to the gold exactly where the scientists want them, creating patterns that control the physical shape and electronic properties of devices that are 10,000 times smaller than the width of a human hair. A paper about the work was published in the journal ACS Nano. “We wanted to develop a mask to place molecules only where we wanted them on a stencil on the underlying gold substrate,” Weiss said. “We knew how to attach molecules to gold as a first step toward making the patterns we need for the electronic function of nanodevices. But the new step here was preventing the patterning on the gold in places where the graphene was. The exact placement of molecules enables us to determine exact patterning, which is key to our goal of building nanoelectronic devices like biosensors.” With the advance, making nanoelectronic and nanobioelectronic devices could be much more efficient than current methods of molecular patterning, which use a technique called nanolithography. Weiss said that could be especially useful for scientists who are trying to place molecular sensors on the surface of gold or other nanomaterials that are used for their sensitivity and selectivity but difficult to work with because of their size. Neurosensors that could measure brain cell and circuit function in real time could reveal new insights into diseases like autism and depression. Ultimately, Weiss said, the researchers hope to be able to stimulate individual brain circuits using sensors so they can predict key chemical differences between function and malfunction in the brain. This knowledge could then be used to develop targets for new generations of treatments for neurological diseases. The paper’s other authors were John Thomas, Shan Jiang, Nathan Weiss and Xiangfeng Duan of UCLA, and Matthew Gethers and William Goddard III of Caltech. Research for the study was conducted in the Electron Imaging Center for Nanomachines and the Nano and Pico Characterization Laboratory, which are both parts of the California NanoSystems Institute. The research was supported by the U.S. Department of Energy, the National Science Foundation, the Caltech EAS Discovery Fund and UCLA. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.


Nashed R.,American University in Cairo | Nashed R.,Characterization Laboratory | Girgis E.,National Research Center of Egypt | Shehata A.,Characterization Laboratory | And 2 more authors.
Asia Communications and Photonics Conference, ACP | Year: 2012

The Effect of introducing CuInSe2 (CIS) Nanocrystals with the electrolyte on the photocurrent response of DSSCs was investigated showing great enhancement in optical switching and electrical stability of DSSCs by improving the electrolyte's reduction rate. © OSA 2012.


Kalpana Nayak I.,Characterization Laboratory | Ramana Rao S.V.,Characterization Laboratory | Kapoor K.,Characterization Laboratory
Journal of Testing and Evaluation | Year: 2015

The crystallographic texture of fabricated components from zirconium alloy has a significant effect on their in-service performance because of texture-dependent properties. Quantitative characterization of this texture in various zirconium alloy tube samples was conducted using pole figure technique and Kearns methodology. Corresponding texture parameters were calculated for both the methods and were found to be similar for samples with strong radial texture. However, the same was not true for samples with transverse texture because of a defocusing error coming due to the geometry of a conventional pole figure technique. Hence, a modified method for such samples by pole figure method was developed which, in addition, solved the difficulties associated with both sample preparation and experiment for the Kearns method or complete pole figure method to a great extent. Copyright © 2014 ASTM International.

Loading Characterization Laboratory collaborators
Loading Characterization Laboratory collaborators